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Nancy Bunin,1 Trudy Small,2 Paul Szabolcs,3 K. Scott Baker,4
Michael A. Pulsipher,5 Troy Torgerson6Defective immune reconstitution is a major barrier to successful hematopoietic cell transplantation (HCT),
and has important implications in the pediatric population. There are many factors that affect immune recov-
ery, including stem cell source and graft-versus-host disease (GVHD). Complete assessment of immune re-
covery, including Tand B lymphocyte evaluation, innate immunity, and response to neoantigens, may provide
insight as to infection risk and optimal time for immunizations. The increasing use of cord blood grafts re-
quires additional study regarding early reconstitution and impact upon survival. Immunization schedules
may require modification based upon stem cell source and immune reconstitution, and this is of particular
importance asmany children have been incompletely immunized, or not at all, before school entry. Additional
studies are needed in children post-HCT to evaluate the impact of differing stem cell sources upon immune
reconstitution, infectious risks, and immunization responses.
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Defective immune reconstitution is a major barrier
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(HCT), regardless of graft orgin [1,2]. Serious1Perelman School of Medicine, University of Pennsylva-
hiladelphia, PA 19104, buninn@email.chop.edu; 2Depart-
of Pediatrics and Laboratory Medicine, Bone Marrow
plant Service, Memorial Sloan-Kettering Cancer Center,
York, NY 10065, smallt@mskcc.org; 3Division of Blood
arrow Transplantation and Cellular Therapies, Child-
Hospital of Pittsburgh of UPMC, Pittsburgh, PA 15224,
zabolcs@chp.edu; 4Clinical Research Division, Fred
inson Cancer Research Center, Seattle, WA 98109,
er@fhcrc.org; 5Division of Hematology/BMT, University
ah, Salt Lake City, UT 84113, michael.pulsipher@hsc.
du); and 6Center for Immunity and Immunotherapies,
rsity of Washington and Seattle Children’s Hospital,
e, WA 98101, troy.torgerson@seattlechildrens.org.
isclosure: See Acknowledgments on page 13.
dence and reprint requests: Michael A. Pulsipher, MD,
on of Hematology/BMT, Primary Children’s Medical
r, University of Utah School of Medicine/Huntsman
r Institute, 50 North Medical Drive, Salt Lake City, UT
(e-mail: michael.pulsipher@hsc.utah.edu).
ovember 10, 2011; accepted November 10, 2011
erican Society for Blood and Marrow Transplantation
/$36.00
6/j.bbmt.2011.11.014infections have been shown to account for
a significant percentage (4%-20%) of late deaths
after HCT [3]. Factors that impact immune recovery
include graft manipulation, stem cell source, and
chronic graft-versus-host disease (cGVHD). The
tempo of immune reconstitution may affect
another important pediatric issue—immunizations.
Many pediatric patients may have been incompletely
immunized, or not at all, before receiving chemo-
therapy and HCT, and the timing, type, and
response to immunizations may play an important
role in preventing morbidity as they begin or reenter
school.
In April 2011, the National Cancer Institute/
National Heart, Lung, and Blood Institute, along
with the Pediatric Blood andMarrowTransplant Con-
sortium sponsored a consensus conference of interna-
tional experts in clinical and biological research into
late effects after HCT convened to review the state
of the science of pediatric studies and identify key areas
for future research. This manuscript will describe the
conclusions shared at that conference relating to as-
sessment of immune status after HCT, differences in
immune status after different types of HCT, and
approaches to immunization in order to effectively
prevent selected viral and bacterial infections after
HCT.
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RECONSTITUTION: USE OF CORD BLOOD
DONORS
There is increasing use of unrelated cord blood
(UCB) for pediatric patients who lack a matched re-
lated donor. Infection-related mortality is the primary
or secondary cause of death (with or without another
major cause such as GVHD) in $50% of deaths
after UCB transplantation (UCBT), with the majority
of them occurring in the first 100 days [4-7]. Use
of cord blood, a donor cell source composed of
predominantly naive cells, raises unique challenges
related to immune reconstitution and cell maturation
that should be considered in the posttransplant period.Opportunistic Infections Negatively Impact
Survival Predominantly within the First 3-6
Months After UCBT
Investigators from the International Bone Marrow
Transplant Registry highlighted the unique features of
infection incidence after UCBT. Outcome after trans-
plantation was analyzed between recipients of either
cord blood (n 5 150) or from marrow that was from
HLA-matched (n 5 367) or mismatched donors
(n 5 83) [8]. Infection-related mortality within 100
days after transplantation was significantly higher
among recipients of mismatched cord blood than
among recipients of either HLA-matched marrow or
mismatched marrow (45%, 21%, and 24%, respec-
tively; P5 .01). However, beyond day 100, the propor-
tions of infection-related deaths were similar in the 3
groups. Importantly, at a later time period there was
a trend toward less serious infection in the UCBT
group corroborating the findings of the International
Bone Marrow Transplant Registry report [8]. It ap-
pears that the profound immune deficit in the first 6
months post-UCBT may be followed by significant
improvements of protective immunity. This period
of improving immuno-competence coincides with
the time of thymic recovery.The Kinetics of Cellular Immune Recovery After
UCBTand Prognostic Factors
Despite some experimental data that neonatal mye-
loid cells are hypofunctional [9], there is no evidence
that post-UCBT the engrafting myeloid granulocytes
or monocytes would have reduced function compro-
mising their migratory, phagocytic, or bacterial killing
capacity [10].Despite the fairly rapid recovery of the in-
nate immune system attaining normal values within the
firstmonths, T lymphocyte recovery is variable and nu-
merically remains below age-matched normal range for
several months. In addition to lymphopenia there is
a coexistent functional compromise that may be ex-
plained by immunosuppressive medications and intrin-sic factors such as antigen naivite and TH1/Tc1
immaturity. Investigators from Lyon and Marseille
[11] compared the tempo of lymphocyte recovery of
112 children who received UCBT with those (n 5
114))who receivedunrelatedbonemarrow transplanta-
tion (UBMT). Notably, median time for CD41 T cell
and natural killer (NK) cell recovery was not dissimilar
in UCBT and UBMT recipients; however, CD81
T cell recovery was delayed after UCBTwith a median
time to reach CD81 T cells .0.25  109/L almost 8
months for UCBT recipients, in contrast to approxi-
mately 3 months for pediatric bone marrow transplant
recipients (P\ .001). Significant B lymphocyte recov-
ery may not commence before 8 to 10 weeks. How-
ever, the recovery of CD191 lymphocytes may
recover faster after UCBT compared with unrelated
donor bonemarrow transplant. In contrast,NK cell re-
covery is prompt in both adults and children attaining
normal frequencies in blood by the first 2 months,
similar to recipients of bone marrow [11-13].Time-Sensitive Predictors of Survival After
Single Cord UCBT Measured Between Day 100
and 1 Year
Dendritic cell and lymphocyte recoverymay impact
on survival posttransplant. Between July 2005 and De-
cember 2007, 93 children with full donor chimerism
following myeloablative conditioning were longitudi-
nally assessed at Duke University for reconstitution of
dendritic cell and T cell subsets, B, and NK cells by
4-color FACS. Measurements were taken at day (D)
100, 180, 270, and 365 to determine thresholds associ-
atedwithoverall survival (OS). Parametersweredichot-
omized at themedian (M) of each time point and hazard
ratios estimated by Cox proportional hazards analysis.
Patients were transplanted for nonmalignant (N5 63)
and malignant diseases (N 5 30). Median age was 2.1
years, 58% male, 36% were 4 of 6, 42% were 5 of 6,
and 23% were 6 of 6 HLA matched. OS at 2 years was
76%.AtD100, lower percentage and absolute numbers
of regulatory T cells (CD251/CD62L1/CD41 regula-
toryT cells [Tregs]) was associated with death (P5 .04
and P5 .02). A higher fraction of ‘‘activated’’ HLA-DR
expressing CD81T cells predicted death at D100 with
marginal significance at 180 and 270, whereas absolute
numbers were significant at D270. At D180, a period
when thymic function may resume after myeloablative
conditioning, recent thymic emigrants was associated
with OS (RTE, CD45RA1/CD62L1 T cells), P5 .01
and P 5 .04. Higher levels of ‘‘plasmacytoid’’
CD1231 dendritic cells were consistently associated
with better outcome after D100 (P\ .05). Major lym-
phocyte subsets, B, NK, CD31, CD41 T cells were
NOT associated with superior outcome except at
D180 when all lymphocytes were combined, exceeding
an absolute leukocyte count .1180/mL (P 5 .04).
Figure 1. Survival according to selected parameters of immune recovery.
8 Biol Blood Marrow Transplant 18:6-15, 2012N. Bunin et al.Figure 1A-Cdepicts a survival curve of patients who are
below or above the median cutoff values for immune
parameters at the designated time point; Figure 1A at
D100, Figure 1B at D180, and Figure 1C at 1 year.
These data demonstrate that different immune cell sub-
sets will have unique kinetics and dynamics of recovery
that confer shifting power in predicting outcome when
tested at different time points within the first year.Nev-
ertheless, by the second half of the first year, superior
pDC and RTE recovery along with a lower activation
state (%HLA-DR) are independently associated with
betterOS.These results should greatly facilitate the de-
velopment of risk models for the early identification of
those at highest risk of death and whomay benefit from
timely immunotherapy interventions.
IMMUNE RECONSTITUTION: EVALUATION
Evaluating Immune Reconstitution of the T Cell
Compartment
T cells play critical roles in host defense against
viral and fungal pathogens. They are essential fordirecting appropriate antibody responses, and they as-
sist in regulating the immune response and maintain-
ing tolerance. Absent or defective T cell responses
therefore have broad implications for infectious sus-
ceptibility and development of GVHD in the post-
transplant period. Traditionally, assessment of the
recovery of T cells after HCT has focused on relatively
crude measures of numbers and function including
simple enumeration of CD3, CD4, and CD8 T cells
and in vitro proliferative responses to mitogens mea-
sured by incorporation of [H3]thymidine into the
DNA of replicating cells or by carboxyfluorescein
diacetate succinimidyl ester (CFSE) dye-dilution stud-
ies using flow cytometry. Improved flow cytometry
and molecular tools have now made a more detailed
analysis of T cell recovery post-HCT possible. These
tools can be applied to evaluate development and
maturation of specific T cell subsets, assess thymic
function, and thymic T cell output, and to evaluate
T cell receptor (TCR) repertoire diversity (Table 1).
Abnormalities in development and maturation of
both CD4 and CD8 T cells may be observed after
Table 1. Assessment of Tand B Cell Compartments Post-HCT
Test Purpose Technique and (Targets) Clinical Availability
T cells Lymphocyte subset analysis Enumeration of T cells Flow cytometry (CD3, CD4, CD8) Readily available
‘‘High content’’ T cell
immunophenotyping
Assessment of T cell maturation
& development
Flow cytometry (CD4, CD8, CD27,
CD45RA, CD45RO, CD57, CCR7)
Readily available in specialty labs
Regulatory T cell (Treg)
Immunophenotyping
Enumeration of Tregs Flow cytometry (CD4, CD25, CD127,
FOXP3, Helios)
Readily available in specialty labs
Mitogen/Antigen induced
proliferation
Assessment of T cell function [H3]Thymidine incorporation or CFSE
dye dilution
Readily available in specialty labs
T cell receptor excision circle
(TREC) analysis
Assessment of thymic function/
recent thymic emigrants
Quantitative real-time PCR of TREC
signal joining (Sj) region.
Available in a few specialty labs
TCR Vb usage by flow
cytometry
TCR repertoire analysis
(overview)
Flow ctyometry (a panel of Vb chains) Readily available in specialty labs
TCR Spectratyping TCR repertoire analysis
(moderately detailed)
PCR and electrophoresis (a panel of
Vb CDR3 regions)
Available in a few specialty labs
TCR sequencing TCR repertoire analysis
(highly detailed)
Deep NextGen sequencing (CDR3
region of the TCRb locus)
Available commercially as
ImmunoSEQ analysis.
B cells Lymphocyte subset analysis Enumeration of B cells Flow ctyometry (CD19, CD20) Readily available
‘‘High content’’ B cell
immunophenotyping
Assessment of B cell
development, maturation,
and class-switching
Flow cytometry (CD10, CD19, CD24,
CD27, CD38, IgA, IgD, IgG, IgM,
BAFF-R)
Readily available in specialty labs
Serum BAFF level Quantification of serum BAFF ELISA (BAFF) Readily available in specialty labs
PCR indicates polymerase chain reaction.
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has been shown to cause skewing to a more activated,
effector memory phenotype in both populations
[14,15]. Pairing of high-resolution immunophenotyp-
ing with measurement of TRECs can provide an esti-
mate of thymic function and naive T cell output after
HCT. Similar to effector T cells, reconstitution of
Tregs can be monitored after HCT by flow cytometry
using an immunophenotyping panel that includes an-
tibodies to CD4, CD25, CD127, and FOXP3.
Evaluating Immune Reconstitution of the B Cell
Compartment
B cell dysfunction, particularly the inability to gen-
erate functional antibody responses, is typically associ-
ated with susceptibility to recurrent sinopulmonary
infections. Several studies have shown that under ideal
circumstances, humoral immune responses to new anti-
gens return as early as 6 months posttransplant even
though immune reconstitution is not yet complete
[16,17]. B cell development and maturation, however,
can be significantly altered in the posttransplant
period, especially in the setting of ongoing immune
suppression or cGVHD. A small number of recent
studies have shown that cGVHD is associated with
marked B cell abnormalities including a general B cell
lymphopenia and altered B cell maturation including
a significant increase in transitional, immature, and
naive B cell subsets with a concomitant decrease in
mature, CD271 memory B cells and class-switched
memory B cells [18-20]. Under normal circumstances,
B cell lymphopenia and absence of mature B cells is
associated with high circulating levels of B cell
activating factor (BAFF/BLyS/TALL-1), which plays
important roles in stimulating proliferation andpreventing apoptosis of B cells. Not surprisingly then,
cGVHD is also associated with high circulating
BAFF levels and in addition, a concomitant decrease
in cell surface expression of the major BAFF receptor
(BAFF-R) on the surface of B cells.
Innate Immunity
A growing understanding of innate and adaptive
immune mechanisms combined with technical ad-
vancements that make assessment of these feasible,
has made it possible to more effectively assess immune
function after HCT. The most extensively studied of
these mechanisms are the Toll-like receptors (TLRs),
which allow cells to respond to a variety of molecules
produced by pathogens including viruses, bacteria,
and fungi In humans. The TLR proteins are encoded
by 10 different genes, each of which encodes a protein
capable of recognizing a different pathogen-derived
product. Recent studies have evaluated whether single
nucleotide polymorphisms in TLR proteins, some of
which are known to affect TLR function, may be asso-
ciated with susceptibility to specific pathogens in the
posttransplant period. Interestingly, 3 studies have
now suggested an association between TLR polymor-
phisms and invasive aspergillosis in patients undergoing
HCT [21-23]. These studies suggest that alterations in
TLR function either in nonhematopoietic cells
(pulmonary epithelial cells, etc.) of the recipient or in
hematopoietic cells from the donor alter susceptibility
to specific pathogens in HCT recipients.
Use of Neoantigens to Assess Functional
Immune Recovery
Measurement of the immune response to vaccina-
tion is an effective method to globally assess immune
10 Biol Blood Marrow Transplant 18:6-15, 2012N. Bunin et al.reconstitution because it requires effective antigen
presentation, B cells capable of responding to antigen,
and adequate T cell help. Unfortunately, routine vac-
cines are not ideal for evaluating immune reconstitu-
tion because these are likely to elicit recall responses
from both donor and host cells, making them an inef-
fective measure of the immune system’s ability to re-
spond to new challenges. In addition, they cannot be
effectively used to evaluate immune responses in
patients receiving supplemental immunoglobulin be-
cause of the presence of antibodies to routine antigens
in the IgG preparations. Assessment of immunocom-
petency in the posttransplant period is therefore
most effectively judged using a neoantigen that neither
the donor nor recipient has been exposed to previ-
ously. Ideally, the neoantigen would also be 1 that
the general population has not been broadly exposed
to so that there would be little measurable antibody
in pooled IgG preparations, allowing responses to be
measured even in individuals whomay be receiving on-
going IgG supplementation. Three most commonly
used neoantigens that fit these criteria include Bacte-
riophage fX174, Rabies vaccine, and Keyhole limpet
hemocyanin.Immune Reconstitution and Immunizations
Most articles addressing vaccination post-HCT
have focused on unmodified HLA matched sibling
transplant recipients, with few studies including large
numbers of unrelated HCT recipients or details about
the extent or amount of immunosuppressive therapy
in patients with cGVHD. There are no studies devoted
exclusively to recipients of cord blood transplants,
a populationwhose response to immunizationsmay dif-
fer significantly from other transplant groups because
of the lack of transfer of memory T and B cells in the
cord blood graft(s). All vaccine guidelines, including
those published in 2009 [24], acknowledge the variabil-
ity in immune reconstitution following alternative do-
nor transplants and the lack of studies assessing
vaccine responses in these patient populations. Al-
though vaccination at fixed times post-HCT will likely
be sufficient for highly immunogenic vaccines such as
tetanus and polio, for others (hepatitis B, pneumococ-
cus, meningococcus, and varicella) some studies have
suggested that vaccination before the acquisition of
critical populations of T and B cells may result in low
response rates with inadequate durability of response.
The 2009 influenza pandemic [25], recent increases in
pertussis [26], and drug-resistant pneumococci [27],
and outbreaks ofmeasles [28] andmumps [29] in immu-
nocompetent individuals highlight the need for
effective revaccination of HCT patients. Vaccine
preventable diseases such as those caused by pneumo-
coccus [30], influenza [31], herpes zoster [32], and
Bordetella pertussis [26,33] cause significantmorbidity and to a lesser extent mortality even in
immunocompetent individuals [34].Many of these infec-
tions occur more frequently in HCT recipients and re-
main a significant cause of morbidity, rehospitalization,
and mortality after successful HCT [35-38]. Following
autologous and allogeneic transplantation, patients lack
immunity against pertussis and rapidly lose protection
against pneumococcus and haemophilus influenza
(reviewed in [24,39]). In the absence of revaccination,
the majority of patients will become susceptible to
measles, mumps, or rubella by 3 to 5 years after.
Since 1995, efforts have been made to immunize
HCT recipients against vaccine preventable diseases
in a standardized fashion. Both the European Group
for Blood and Marrow Transplantation [40] and the
Centers forDisease Control [41] have published guide-
lines that differ in the number of recommended doses
of tetanus, polio, and Haemophilus influenza vaccines,
as well as the time to initiate revaccination [24,39]. In
2009 [24], an international committee of infectious dis-
ease and transplant physicians met under the auspices
of the Center for International Blood and Marrow
Transplant Research, to develop an updated, unified
international set of vaccine guidelines for autologous
and allogeneic transplant recipients. These guidelines
differ from prior guidelines primarily by (1) inclusion
of the 7-valent protein conjugated pneumococcal vac-
cine (PCV7) (3 monthly doses) in all patients starting
at 3 to 6 months post-HCT, followed by PPV23 in
patients without cGVHD; (2) use of the live varicella
vaccine in select patient groups starting at 24 months
post-HCT, and (3) optional use of vaccines licensed
since 2005 such as the tetanus toxoid, reduced diphthe-
ria toxoid, and acellular pertussis vaccine (Tdap) for
adolescents and adults, the recombinant human papil-
loma vaccine [42], and the protein-conjugated menin-
gococcal vaccine [43]. An important limitation of
both current and past HCT vaccine guidelines is the
recommendation that all patients should be vaccinated
at fixed times post-HCT. This does not take into ac-
count the variable kinetics of immune reconstitution
on the basis of age, donor, stem cell source [44-48] or
use of monoclonal antibodies such as anti-CD20 [49].
In addition, guidelines can quickly become outdated
because of licensing of new vaccines [50,51], resulting
in changes in recommendations from the Advisory
Committee on Immunization Practices to better
protect immunocompetent patients.Immunogenicity of Vaccines Post-HCT
Multiple studies have demonstrated the superior
response of patients reimmunized with 3 doses of tet-
anus toxoid, inactivated polio vaccine, and/or the pro-
tein conjugated Haemophilus influenza vaccine (HIB)
compared with those given a single vaccine [52-59]
as well as the benefit of donor immunization before
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tetanus toxoid [57-59]. In addition, published reports
have shown the poor or transient responses of HCT
recipients to pure polyscaccharide vaccines such as
PPV23 and MSV4 [59-64] compared with the
protein conjugated polysaccharide vaccines (ie, HIB,
Prevnar 7) [65-67].
The results of a randomized, prospective multicen-
ter trial performed in 158 patients (aged 5-65 years of
age) was reported by Cordonnier et al. [68] in 2009.
All patients received an allogeneic HCT and myeloa-
blative conditioning. Approximately 65% of patients
in both groups had no acute GVHD and limited or
no cGVHD was seen in 56% and 33% of patients, re-
spectively. The study demonstrated similar responses
in both groups when tested 1 month after the third
PCV7 dose ([79% versus 82%, P 5 .64), although
the percentage of patients who still had positive titers
to all 7 seroytpes at 24 months post-HCT was signifi-
cantly lower in patients vaccinated early versus later
post-HCT (59% versus 83%; P 5 .013). As Prevnar7
is no longer manufactured, a multicenter, prospective
international trial of a series of 3 PCV13 immuniza-
tions followed by a booster Prevnar13 and the PPV23
in adults and children is currently underway.Vaccines Against Viral Diseases
Vaccination against hepatitis B is often mandatory
for entry to school and required for certain jobs [69]. In
a study of 267 allogeneic transplant recipients immu-
nized with rHBV following acquisition of preset mile-
stones of immune competence, 64% seroconverted
[70] including 73% of 99 children, and 59% of 168
adults (P 5 .02). In multivariate analyses, response
was adversely affected by age .18 years (P \ .01)
and history of prior cGVHD (P\ .0001) but not by
donor type, use of T cell depletion, adoptive immuno-
therapy, or posttransplant rituximab [70]. Evaluation
of serial titers in 98 patients demonstrated that 80
remained seropositive 5 years after their last vaccine.
As the time to develop normal numbers of
CD271IgD1 memory B cells and CD4 helper cells
varies among different allogeneic HCT populations
[71], surrogate markers such as these may be instru-
mental in determining the need and timing of booster
immunizations to maintain durable protection.
The majority of children will become seronegative
for measles, mumps, and rubella (MMR) by 3 years
post-HCT. King et al. [72] demonstrated that 68% of
children given measles, mumps, rubella at a median of
48 months post-HCT responded to all 3 attenuated vi-
ruses [72]. Also, there are limited data on the immuno-
genicity and durability of response to MMR following
alternative donor HCT or response to mumps follow-
ing any type of HCT [73]. Of 113 children immunized
with MMR at Memorial Sloan-Kettering Cancer Cen-ter following an HLA matched sibling (n 5 60) or un-
related (n5 38)HCT, the response was 70% following
a single MMR, including 42 recipients of an HLA
matched relatedHCTand 27 recipients of an unrelated
HCT (P 5 NS). There were no significant adverse
reactions, even in nonresponders [73].
There is widespread use of influenza vaccines, but
there is limited data on response of HCT recipients to
the killed influenza vaccine, particularly the H1N1
strain. Studies have shown a relatively poor response
[74,75]. Although immunization with the inactivated
influenza vaccine has been shown by Machado et al.
[74] to decrease the risk of influenza when adminis-
tered.6 months post-HCT (2 of 19 vaccinated versus
12 of 24 unvaccinated), the majority of serious infec-
tions occur earlier post-HCT, when vaccine response
to influenza is very poor.
Because licensing of the live attenuated varicella
vaccine (LAVV) in 1995, an increasing number of chil-
dren, adolescents, and young adults undergoing HCT
or donating stem cells have been protected against var-
icella by 1 or 2 doses of the LAVV. As the LAVV gen-
erally induces lower levels of antibody titers than
natural infection, with titers that decrease over time
postvaccination, 2 LAVV are recommended for veri-
cella zoster seronegative individuals [76,77]. Only
a limited number of studies have evaluated the
LAVV in children post-HCT. In the study by Sauer-
brei [78], 15 children (median age 18 months) received
LAVV following an autologous (n 5 7) or allogeneic
(n 5 8) HCT. Patients had a circulating lymphocyte
count of .1000/mL, IgG .500 mg/dL, and a positive
skin test to a recall antigen such as Candida. Studies
have documented safety and seroconversion in
.60% of evaluable patients [79,80].
Vaccines Approved Since 2005
Protein-conjugated meningococcal vaccines. In
2010 [81], a quadravalent protein conjugated menin-
gococcal vaccine was licensed in the United States.
Unlike the pure polysaccharide vaccine, this vaccines
elicits a T cell-dependent B cell response yielding
the potential to induce long-term memory. There
have been small studies showing either poor response,
or rapid decrease in response following a single immu-
nization [82].
Tdap
Currently there are 2 vaccines containing Tdap ap-
proved for individuals 10 to 55 years of age. These
vaccines contain similar amounts of tetanus and diph-
theria toxoid, but different amounts of pertussis toxoid
(2.5 versus 8 mg/dose). Response to a single Tdap is
poor [83,84] in allogeneic or autologous HCT
recipients likely in part because of the small amount
of pertussis toxoid contained in the vaccine and the
12 Biol Blood Marrow Transplant 18:6-15, 2012N. Bunin et al.limited numbers of memory specific T and B cells
transferred from the graft capable of a pertussis
response.
Recommendations: Immune Reconstitution
T cells
Formost patients, T cell reconstitution after trans-
plant can be adequatelymonitored using a combination
of lymphocyte subset analysis, ‘‘high content’’ immu-
nophenotyping, and evaluation of T cell proliferative
capacity to mitogens. In patients who demonstrate
poor T cell reconstitution, persistent susceptibility to
viral or fungal infections, or significant autoimmu-
nity/GVHD, additional testing may be of benefit to
more completely assess thymic T cell output, Treg
numbers, T cell function, and TCR diversity.
B cells
As discussed, B cell responses to neoantigen return
approximately 6 months after transplant, we therefore
suggest that this is an appropriate time to begin to fol-
low B cell reconstitution and maturation by ‘‘high-
content’’ B cell immunophenotyping (including cell
surface BAFF-R expression). Over time, a normal mat-
uration of B cells from immature to mature naive then
to a mature memory phenotype (CD271) should be
observed. Persistently poor B cell development with
an absence of memory B cells, decreased cell surface
BAFF-R levels, and high serumBAFFmay be indicative
of cGVHD [8-10]. In addition, these studies can help to
identify those patients whomay need further evaluation
by neoantigen immunization and/or ongoing treatment
with supplemental immunoglobulin.
Neoantigen challenge
Very valuable to assess functional immunity in pa-
tients who have evidence of poor or incomplete im-
mune reconstitution (based on immunophenotyping)
or who have cGVHD. Rabies vaccine is currently
available clinically but Bacteriophage and Keyhole
limpet hemocyanin are available only on study proto-
cols. Patients who demonstrate poor responses to neo-
antigen challenge should be considered for ongoing
antimicrobial prophylaxis and immunoglobulin sup-
plementation (IVIg, SCIg, etc.).
Recommendations: Vaccination
Given the increased use of unrelated and cord
blood donors and of conditioning regimens of varying
intensity over the last 10 years, it remains unclear
whether vaccination according to fixed times post-
HCT will protect the majority of HCT recipients.
All vaccine guidelines, including those published in
2009 [24], acknowledge the variability in immune re-
constitution following alternative donor transplantsand the lack of studies assessing vaccine responses in
these patient populations. Although vaccination at
fixed times post-HCTwill likely be sufficient for highly
immunogenic vaccines such as tetanus and polio, for
others such as hepatitis B, pneumococcus, meningo-
coccus, and varicella, some studies have suggested
that vaccination before the acquisition of critical popu-
lations of T and B cells may hinder response rates and
the durability of response. Current recommendations
to immunize with live attenuated viral vaccines at 24
months are somewhat arbitrary, particularly because
studies have shown earlier vaccination is safe. Earlier
vaccination with live vaccines would be particularly
useful in children returning to school during the first
transplant year who are vulnerable to these infections.
Current vaccine guidelines therefore recommend
yearly inactivated influenza vaccination in patients
$6 months post-HCT, strongly advocate immuniza-
tion of household members and caretakers, and stress
prompt evaluation of patients with respiratory symp-
toms so that early antiviral therapy can be instituted
in infected patients [24].
In 2011, the Advisory Committee on Immuniza-
tion Practices recommended a 2-dose series of conju-
gated meningococcal vaccine in individuals with
functional or congenital asplenia, complement defi-
ciency, or HIV infected individuals [83]. Consideration
of a similar 2-dose series administered 2 months apart
should be evaluated in HCT recipients.
The 2009 Center for International Blood and
Marrow Transplant Research guidelines recommen-
ded a series of Tdap containing 8 mg of pertussis tox-
oid/dose [24]. The effectiveness of this strategy is
currently being tested.FUTURE RESEARCH
The increasing use of cord blood as an alternative
HSC source requires additional research into the ki-
netics of immune reconstitution and its impact upon
outcome. In addition, it is unknown as to whether
cord blood outcomes may be predicted based upon
varying subsets of immune recovery.
Several studies have suggested the value of assess-
ing specific parameters of immune reconstitution as
biomarkers for cGVHD and predictors of outcome.
Recent studies have suggested B cell immunopheno-
typing and serum BAFF levels may be particularly in-
formative. These studies should be extended to include
more patients in order to validate these findings in
a broader patient population. In addition, the increas-
ing availability of next-generation sequencing technol-
ogies could be incorporated to allow the further study
of polymorphic variants of TLR and other immunity-
related proteins in transplant patients. Identified vari-
ants may be useful to stratify risk and possibly identify
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antifungal prophylaxis, etc.) in the posttransplant
period.
In an ideal setting, neoantigen could be used to
evaluate the reconstitution of functional immunity in
every patient after transplant. Unfortunately, the cost
(sometimes not covered by insurance) and the clinical
inaccessibility of common neoantigens impedes their
regular use. A prospective study of neoantigen re-
sponses in a wide variety of HCT scenarios should
be a high priority to evaluate the clinical utility of
this approach for identifying patients at risk of serious
late infections and to determine how these tools
may be most effectively used and made more broadly
available.
Future vaccine trials should ideally include parallel
assessments of in vitro parameters of immune reconsti-
tution to determine whether surrogate markers of im-
mune reconstitution can predict vaccine response.
In vitro correlates of vaccine responses might allow
earlier revaccination of patients with the requisite T
and B cell populations and prevent premature vaccina-
tion and/or risk in patients unable to respond. Studies
assessing the recombinant human papilloma virus vac-
cine, particularly in children with increased risk such as
those with Fanconi anemia or certain primary immu-
nodeficiency diseases, are warranted, as are trials eval-
uating earlier vaccination of children without GVHD
against varicella, MMR. Current recommendations to
immunize with live-attenuated viral vaccines at 24
months are somewhat arbitrary, particularly because
studies have shown earlier vaccination is safe. This
would be particularly useful in children returning to
school during the first transplant year who are vulner-
able to these infections.ACKNOWLEDGMENTS
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